Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2014-05-22 Board/Management Inform…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is the appointment of a new director, Wendy S. Johnson, to the board of AmpliPhi Biosciences Corporation. The document details her background and the board appointment but does not contain financial statements or earnings data. The primary focus is on a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is under 5,000 characters and is not a report publication announcement or certification. Therefore, the correct classification is MANG with high confidence.
2014-05-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is the resignation of the Chief Financial Officer and Principal Financial and Accounting Officer, effective May 23, 2014, and the arrangement for consulting services post-resignation. This corresponds to an announcement of changes in senior management. The document is not a full report but a regulatory filing announcing management changes, fitting the Board/Management Information category (MANG). The document length is short and focused solely on management change, confirming this classification.
2014-05-20 English
10-Q
Interim / Quarterly Report Q1 2014
2014-05-20 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing with the SEC. It specifically states that the registrant, AmpliPhi Biosciences Corporation, is unable to file its quarterly report on Form 10-Q for the quarter ended March 31, 2014, within the prescribed time period. The document explains the reasons for the delay and requests additional time to file the report. It does not contain the actual 10-Q report or substantive financial data but is rather an announcement related to the late filing of a quarterly report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a delay, not the report itself.
2014-05-15 English
Regulatory Filings 2014
Regulatory Filings
2014-05-08 English
DEF 14A
Proxy Solicitation & Information Statement
2014-04-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.